Hodgkin lymphoma is a challenging disease and a cure, with current therapy, is possible in some but not all patients. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses these challenges and the unmet needs in the treatment of Hodgkin lymphoma.
Dr Stephen Ansell presented an abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1’ (Abstract number 7503) at the ASCO annual meeting, June 3-7, 2022.
Question:
1. What are the challenges and unmet needs in the frontline treatment of Hodgkin lymphoma? (0:16)
Disclosures: Stephen Ansell has received grant/research support from ADC Therapeutics, Affimed, BMS, Pfizer, Regeneron, SeaGen and Takeda and is on the advisory board for Affimed.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
